Colorectal signet-ring cell carcinoma (SRCC) is a rare subtype of malignant adenocarcinomas. Its biomarker and molecular characteristics remain controversial, and there are no specific therapeutic targets and strategies for clinical treatment. A retrospective study was performed and the extracted data included patients’ clinical variables and genomics (either 19-gene or 1021-gene panel NGS). From 2010 to 2021, 64 patients were included. The blood groups of 27 (42.2%), 18 (28.1%), 12 (18.8%), and 7 (10.9%) patients were O, A, B, and AB, respectively. We found that O was a unique blood group which had better prognosis different from non-O blood groups, characterized by a low frequency of KRAS mutations, a high frequency of heterozygous at each HLA class I locus and greater numbers of tumor mutational burden (TMB). Patients with blood group A with high frequency KRAS mutations and patients with blood group B with anemia and metabolic abnormalities had worse OS and needed targeted treatment. The study initially revealed genomic changes in SRCC patients with different blood groups and could advance the understanding and precision treatment of the colorectal SRCC. Blood group O might be a novel target for immunotherapy of colorectal SRCC.